fidaxomicin and Streptococcal-Infections

fidaxomicin has been researched along with Streptococcal-Infections* in 3 studies

Other Studies

3 other study(ies) available for fidaxomicin and Streptococcal-Infections

ArticleYear
Cadazolid Does Not Promote Intestinal Colonization of Vancomycin-Resistant Enterococci in Mice.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1

    The promotion of colonization with vancomycin-resistant enterococci (VRE) is one potential side effect during treatment of Clostridium difficile-associated diarrhea (CDAD), resulting from disturbances in gut microbiota. Cadazolid (CDZ) is an investigational antibiotic with potent in vitro activity against C. difficile and against VRE and is currently in clinical development for the treatment of CDAD. We report that CDZ treatment did not lead to intestinal VRE overgrowth in mice.

    Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Clostridioides difficile; Colony Count, Microbial; Diarrhea; Enterocolitis, Pseudomembranous; Fidaxomicin; Intestines; Metronidazole; Mice; Microbial Sensitivity Tests; Oxazolidinones; Streptococcal Infections; Treatment Outcome; Vancomycin; Vancomycin Resistance; Vancomycin-Resistant Enterococci

2016
[Antibiotics: the race continues].
    Medizinische Monatsschrift fur Pharmazeuten, 2012, Volume: 35, Issue:9

    Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Clostridioides difficile; Drug Resistance, Multiple, Bacterial; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Streptococcal Infections; Streptococcus pneumoniae; Streptococcus pyogenes

2012
'Game changer' antibiotic and others in works for superbug.
    Nature medicine, 2011, Volume: 17, Issue:1

    Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Clostridioides difficile; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Metronidazole; Secondary Prevention; Streptococcal Infections; United States; United States Food and Drug Administration; Vancomycin

2011